<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627978</url>
  </required_header>
  <id_info>
    <org_study_id>0707009284</org_study_id>
    <nct_id>NCT00627978</nct_id>
  </id_info>
  <brief_title>Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons</brief_title>
  <official_title>Phase II Study of Ixabepilone in Patients With Metastatic Breast Cancer and a Prospective Evaluation of Its Effects on the Ultrastructure of Neurons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives&#xD;
&#xD;
        -  Assess ultrastructure changes in dermal myelinated nerves of patients who receive&#xD;
           ixabepilone chemotherapy&#xD;
&#xD;
        -  Detailed characterization of peripheral neuropathy in patients who receive ixabepilone&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  Clinical benefit rate&#xD;
&#xD;
        -  Time to progression ( TTP)&#xD;
&#xD;
        -  Toxicity&#xD;
&#xD;
        -  Exploratory studies:&#xD;
&#xD;
             -  Relation of MDR 1 and TRKA polymorphisms to evolution of ultrastructural neurologic&#xD;
                changes observed in neurons.&#xD;
&#xD;
             -  Relation of NGF, IL8, and IL10 to the development of clinical symptoms and&#xD;
                ultrastructural changes in neurons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patient population:&#xD;
&#xD;
        -  Stage 4 breast cancer&#xD;
&#xD;
        -  Resolution from toxicity of prior therapy to ≤ CTC grade 1 ( except alopecia)&#xD;
&#xD;
        -  No limit on prior number of therapies to treat cancer&#xD;
&#xD;
        -  Adequate organ function&#xD;
&#xD;
        -  Life expectancy greater than 3 months&#xD;
&#xD;
      Treatment: ixabepilone 40 mg/m2 Q3w over 3 hours&#xD;
&#xD;
      Evaluation on Study:&#xD;
&#xD;
      I. Efficacy evaluation:&#xD;
&#xD;
        -  Baseline CT chest, abdomen and pelvis and bone scan within 4 weeks of starting therapy&#xD;
&#xD;
        -  Evaluation of disease every 2 cycles of chemotherapy&#xD;
&#xD;
        -  Ongoing toxicity evaluation using NCI CTC 3.&#xD;
&#xD;
      II. Neurological evaluation:&#xD;
&#xD;
        -  Detailed neurologic exam using Neuropathy Assessment Instrument (represents a standard&#xD;
           neurological exam)&#xD;
&#xD;
        -  Serum NGF, IL 8,10, prior to starting therapy and prior to each cycle of ixabepilone&#xD;
&#xD;
        -  DNA for assessment of TRK A and MDR1 polymorphisms&#xD;
&#xD;
        -  Punch biopsy of skin prior to starting therapy and after every 2 cycles. Laboratory&#xD;
           evaluation of peripheral nerve biopsies will be conducted at Rockefeller University&#xD;
           under the direction of Dr. Carlson in Dr. Strickland's Lab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axons With Abnormal Morphology</measure>
    <time_frame>Baseline and Over 7 cycles of treatment, approximately 21 weeks</time_frame>
    <description>Digital photographs for morphometry were captured at a magnification of 8000-16,000x and the photos were uploaded onto an imaging platform of transmission electron microscope (iTEM) (Olympus, Mu¨nster, Germany). The figures were enlarged by 50%, and an individual linear array was used to measure the axonal diameter (cross-sectional area) and the number of unmyelinated axons per Remak Schwann cell was enumerated according to the established methodology.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ixabepilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are treated with Ixabepilone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>ixabepilone 40 mg/m2 Q3w over 3 hours</description>
    <arm_group_label>Ixabepilone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of adenocarcinoma originating in the breast.&#xD;
&#xD;
          -  Evidence that the cancer is metastatic or locally advanced and not curable by local&#xD;
             measures (i.e., surgery, radiation).&#xD;
&#xD;
        NOTE: There is no limit on number of prior chemotherapy regimens received.&#xD;
&#xD;
          -  Karnofsky performance status (KPS) score of 70 - 100; (Appendix 1).&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate recovery of drug related toxicities from prior systemic therapy (recovery to&#xD;
             &lt; = Grade 1 except for Grade 2 fatigue and alopecia).&#xD;
&#xD;
          -  Adequate recovery from recent surgery and radiation therapy. At least one week must&#xD;
             have elapsed from the time of a minor surgery and/or focal/palliative radiation&#xD;
             therapy; at least 3 weeks for major surgery and other radiation therapy.&#xD;
&#xD;
          -  Women or Men, age &gt; = 18 years.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Hematologic function with absolute neutrophils ≥ 1,500/mm3 and/or platelets &gt;&#xD;
                  125,000/mm3&#xD;
&#xD;
               -  Hepatic function with serum bilirubin less than 1.5 times the upper institutional&#xD;
                  limits of normal, ALT ≤ 2.5 times the upper institutional limits of normal (≤ 5&#xD;
                  times the upper institutional limits of normal if documented hepatic metastases&#xD;
                  are present)&#xD;
&#xD;
               -  Renal function with serum creatinine ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men with partners who are of childbearing&#xD;
             potential must be using an adequate method of contraception to avoid pregnancy&#xD;
             throughout the study and for up to 4 weeks after the study in such a manner that the&#xD;
             risk of pregnancy is minimized.&#xD;
&#xD;
        WOCBP include any female who has experienced menarche and who has not undergone successful&#xD;
        surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy)&#xD;
        or is not postmenopausal (defined as amenorrhea &gt; = 12 consecutive months; or women on&#xD;
        hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH)&#xD;
        level &gt; 35 mIU/mL). Even women who are using oral, implanted or injectable contraceptive&#xD;
        hormones or mechanical products such as an intrauterine device or barrier methods&#xD;
        (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where&#xD;
        partner is sterile (e.g., vasectomy), should be considered to be of child bearing&#xD;
        potential.&#xD;
&#xD;
        - WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or&#xD;
        equivalent units of HCG) within 72 hours prior to the start of study medication.&#xD;
&#xD;
        Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
        study, she should inform her treating physician immediately.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with known and active brain and/or leptomeningeal metastases should be&#xD;
             excluded from this clinical trial because of their poor prognosis and because they&#xD;
             often develop progressive neurologic dysfunction that would confound the evaluation of&#xD;
             neurologic and other adverse events.&#xD;
&#xD;
          -  CTC Grade 2 or greater neuropathy (motor or sensory) at study entry.&#xD;
&#xD;
          -  Prior treatment with ixabepilone.&#xD;
&#xD;
          -  Serious intercurrent infections, or nonmalignant medical illnesses that are&#xD;
             uncontrolled or whose control may be jeopardized by the complications of this therapy,&#xD;
             including, but not limited to: ongoing or active infection, symptomatic congestive&#xD;
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Known history of HIV infection.&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Patients may not be receiving any other concurrent chemotherapy, hormonal therapy,&#xD;
             immunotherapy regimens or radiation therapy, standard or investigational.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ixabepilone.&#xD;
&#xD;
          -  Known prior severe hypersensitivity reactions to agents containing CremophorEL.&#xD;
&#xD;
          -  Patients may not be receiving any prohibited therapies and/or medications.&#xD;
&#xD;
          -  Pregnant and lactating women are excluded from the study because the risks to an&#xD;
             unborn fetus or potential risks in nursing infants are unknown.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Vahdat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <results_first_submitted>February 2, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ixabepilone</title>
          <description>Participants are treated with Ixabepilone.&#xD;
ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No treatment with Ixabepilone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ixabepilone</title>
          <description>Participants are treated with Ixabepilone.&#xD;
ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants receive no intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" lower_limit="39" upper_limit="70"/>
                    <measurement group_id="B2" value="51" lower_limit="35" upper_limit="63"/>
                    <measurement group_id="B3" value="54.4" lower_limit="35" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Axons With Abnormal Morphology</title>
        <description>Digital photographs for morphometry were captured at a magnification of 8000-16,000x and the photos were uploaded onto an imaging platform of transmission electron microscope (iTEM) (Olympus, Mu¨nster, Germany). The figures were enlarged by 50%, and an individual linear array was used to measure the axonal diameter (cross-sectional area) and the number of unmyelinated axons per Remak Schwann cell was enumerated according to the established methodology.</description>
        <time_frame>Baseline and Over 7 cycles of treatment, approximately 21 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>Participants are treated with Ixabepilone.&#xD;
ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment with Ixabepilone</description>
          </group>
        </group_list>
        <measure>
          <title>Axons With Abnormal Morphology</title>
          <description>Digital photographs for morphometry were captured at a magnification of 8000-16,000x and the photos were uploaded onto an imaging platform of transmission electron microscope (iTEM) (Olympus, Mu¨nster, Germany). The figures were enlarged by 50%, and an individual linear array was used to measure the axonal diameter (cross-sectional area) and the number of unmyelinated axons per Remak Schwann cell was enumerated according to the established methodology.</description>
          <units>percentage of axons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Axons grade 0 (normal) or 1 morphology baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axons grade 0 (normal) or 1 morphology Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">Treatment was not given to the control arm so no value is available for post-7 cycles of treatment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axons grade 3 or 4 morphology baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axons grade 3 or 4 morphology Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="NA">Treatment was not given to the control arm so no value is available for post-7 cycles of treatment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and Other [Not Including Serious] Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ixabepilone</title>
          <description>Participants are treated with Ixabepilone.&#xD;
ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants are not treated with Ixabepilone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Vahdat, MD</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>646-962-9888</phone>
      <email>ltv2001@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

